PS5 - 24. Add-on treatment of GLP-1 agonists in type 2 diabetics treated with insulin: an observational study

被引：0
|
作者：
Wouter T. Zandee
Maria A. Sleddering
Ingrid Jazet
Petronella H.L.M. Geelhoed-Duijvestijn
Aart H. Bootsma
机构：
[1] Medisch Centrum Haaglanden,
[2] Leids Universitair Medisch Centrum,undefined
来源：
Nederlands Tijdschrift voor Diabetologie | 2011年 / 9卷 / 3期
关键词：
Public Health; Glucose; Insulin Resistance; Observational Study; Average Weight;
D O I：
10.1007/s12467-011-0049-9
中图分类号：
学科分类号：
摘要：
In The Netherlands GLP-1 agonists are used to treat type 2 diabetes in combination with metformin and SU-derivatives. Thus far, only few data have been published on the use of GLP-1 agonists in combination with insulin. We studied patients with severe insulin resistance that cannot be treated to target even with high doses of insulin.
引用
收藏
页码：107 / 107
相关论文
共 50 条
  • [1] Add-on treatment of GLP-1 based therapy in patients with type 2 diabetes treated with insulin: an observational study
    Zandee, W. T.
    Sleddering, M. A.
    Jazet, I.
    Bootsma, A. H.
    Geelhoed-Duijvestijn, P. H. L.
    [J]. DIABETOLOGIA, 2012, 55 : S299 - S299
  • [2] GLP-1 receptor agonists and basal insulin in type 2 diabetes
    Young, Laura A.
    Buse, John B.
    [J]. LANCET, 2014, 384 (9961): : 2180 - 2181
  • [3] Predictors of Responsiveness to GLP-1 Receptor Agonists in Insulin-Treated Patients with Type 2 Diabetes
    Gavigan, Colleen
    Donner, Thomas
    [J]. JOURNAL OF DIABETES RESEARCH, 2023, 2023
  • [4] Factors Predicting GLP-1 Receptor Agonists Efficacy in Type 2 Diabetes Mellitus Treatment: A Retrospective Observational Study
    Duvnjak, Lea
    Blaslov, Kristina
    [J]. DIABETES, 2016, 65 : A572 - A572
  • [5] GLP-1 agonists and insulin in obese insulin-treated patients with type 2 diabetes: combined treatment or substitution? Weight and metabolic benefits
    Bertoin, F.
    Paoli, A.
    Ancelle, D.
    Decoudier, B.
    Francois, M.
    Lukas-Croisier, C.
    Bertin, E.
    Crouzet, M.
    Moysset, P.
    Hecart, A. -C.
    Malgrange, D.
    Delemer, B.
    [J]. DIABETOLOGIA, 2012, 55 : S298 - S299
  • [6] Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
    Nauck, Michael A.
    Meier, Juris J.
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2019, 181 (06) : R211 - R234
  • [7] Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis
    Marco Castellana
    Angelo Cignarelli
    Francesco Brescia
    Sebastio Perrini
    Annalisa Natalicchio
    Luigi Laviola
    Francesco Giorgino
    [J]. Scientific Reports, 9
  • [8] Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis
    Castellana, Marco
    Cignarelli, Angelo
    Brescia, Francesco
    Perrini, Sebastio
    Natalicchio, Annalisa
    Laviola, Luigi
    Giorgino, Francesco
    [J]. SCIENTIFIC REPORTS, 2019, 9 (1)
  • [9] GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy
    Scheen, Andre J.
    [J]. DRUGS, 2024,
  • [10] Real-world characteristics of patients with type 2 diabetes on basal insulin initiating add-on GLP-1 analogue therapy
    Dalal, M. R.
    Ling, Z.
    Davis, K. L.
    Meyers, J. L.
    DiGenio, A.
    [J]. DIABETOLOGIA, 2012, 55 : S403 - S404
12345